409 related articles for article (PubMed ID: 18155370)
1. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
Sun W; Zhang N; Li A; Zou W; Xu W
Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
[TBL] [Abstract][Full Text] [Related]
2. Release mechanism studies on TFu nanoparticles-in-microparticles system.
Sun W; Zhang N; Li X
Colloids Surf B Biointerfaces; 2012 Jun; 95():115-20. PubMed ID: 22424827
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration.
Sun W; Zou W; Huang G; Li A; Zhang N
J Drug Target; 2008 Jun; 16(5):357-65. PubMed ID: 18569280
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Liu J; Li X; Cheng YN; Cui SX; Chen MH; Xu WF; Tian ZG; Makuuchi M; Tang W; Qu XJ
Eur J Pharmacol; 2007 Nov; 574(1):1-7. PubMed ID: 17904544
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery.
Liu C; Liu D; Bai F; Zhang J; Zhang N
Drug Deliv; 2010 Jul; 17(5):352-63. PubMed ID: 20387993
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
Zhang J; Li M; Liu Z; Wang L; Liu Y; Zhang N
Int J Nanomedicine; 2014; 9():2741-51. PubMed ID: 24920908
[TBL] [Abstract][Full Text] [Related]
7. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting.
Lai LF; Guo HX
Int J Pharm; 2011 Feb; 404(1-2):317-23. PubMed ID: 21094232
[TBL] [Abstract][Full Text] [Related]
8. The in vitro anti-tumor efficacy and the pharmacokinetics of N3-o-toluyl-fluorouracil loaded nanosuspension (TFu-LNS).
Li M; Zhang J; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2013 May; 9(5):801-10. PubMed ID: 23802409
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of liposome-encapsulated codrug LMX.
Zhong Y; Wang J; Wang Y; Wu B
Int J Pharm; 2012 Nov; 438(1-2):240-8. PubMed ID: 22981689
[TBL] [Abstract][Full Text] [Related]
10. The effects of lyophilization on the stability of liposomes containing 5-FU.
Glavas-Dodov M; Fredro-Kumbaradzi E; Goracinova K; Simonoska M; Calis S; Trajkovic-Jolevska S; Hincal AA
Int J Pharm; 2005 Mar; 291(1-2):79-86. PubMed ID: 15707734
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration.
Yang YW; Lee JS; Kim I; Jung YJ; Kim YM
Eur J Pharm Biopharm; 2007 May; 66(2):260-7. PubMed ID: 17182232
[TBL] [Abstract][Full Text] [Related]
12. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
13. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
14. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.
Ye J; Wang Q; Zhou X; Zhang N
Int J Pharm; 2008 Mar; 352(1-2):273-9. PubMed ID: 18054182
[TBL] [Abstract][Full Text] [Related]
15. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles.
Du B; Yan Y; Li Y; Wang S; Zhang Z
Pharm Dev Technol; 2010; 15(4):346-53. PubMed ID: 19769532
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes.
Du B; Li Y; Li X; A Y; Chen C; Zhang Z
Int J Pharm; 2010 Jan; 384(1-2):140-7. PubMed ID: 19800955
[TBL] [Abstract][Full Text] [Related]
17. Potential dopamine prodrug-loaded liposomes: preparation, characterization, and in vitro stability studies.
Carafa M; Marianecci C; Di Marzio L; De Caro V; Giandalia G; Giannola LI; Santucci E
J Liposome Res; 2010 Sep; 20(3):250-7. PubMed ID: 19958070
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil into poly(lactide-co-glycolide) nanoparticles.
McCarron PA; Hall M
Int J Pharm; 2008 Feb; 348(1-2):115-24. PubMed ID: 17709217
[TBL] [Abstract][Full Text] [Related]
19. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
Padamwar MN; Pokharkar VB
Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
[TBL] [Abstract][Full Text] [Related]
20. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate.
Paliwal R; Paliwal SR; Mishra N; Mehta A; Vyas SP
Int J Pharm; 2009 Oct; 380(1-2):181-8. PubMed ID: 19576973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
